Skip to Main Content

News : News Release

Cadwalader Advises HealthCare Royalty Partners in $150 Million Royalty Agreement with Karyopharm Therapeutics

October 15, 2019

Cadwalader advised HealthCare Royalty Partners in connection with a revenue interest financing transaction with Karyopharm Therapeutics for up to $150 million to support the ongoing development and commercialization of XPOVIOTM (selinexor), Karyopharm’s oral SINE compound that is currently marketed in the United States for the treatment of patients with heavily pretreated multiple myeloma.

The Cadwalader team was led by partner Ira Schacter and included Joo Kim.

First 10b5-1 Insider Trading Case Raises Compliance Issues

A Key Pitfall of Restricted Subsidiaries in Loan Agreements

Insider Trading and Off-Channel Communications in the Age of Remote and Hybrid Work Environments

Getting the Message: What to Do (and Worry About) With Ephemeral Messaging Apps and Personal Devices

Sponsors Seek Unique Revolver Control

Cadwalader Guides PW Partners In Cooperation Agreement With BJ’s Restaurants

Cadwalader and Citizens Budget Commission Support New York Court of Appeals Revival of Constitutional Challenge to New York Property Tax System

_____________________________________________

Wes Misson Named a 2024 “Leader in the Law”

Mercedes Tunstall Named a Top 2024 Fintech/AI Lawyer

Andrew Karp Drawn to Cadwalader’s ‘Strong Relationships With Financial Markets’

IFLR Names Linda Swartz ‘Lawyer of the Year’ Finalist

Cadwalader Shortlisted for Multiple 2024 Women in Business Law Awards